CRESCENT BIOPHARMA, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

CRESCENT BIOPHARMA, INC. reported Cash And Cash Equivalents At Carrying Value of $213.19 million for the year ending 2025.

  • CRESCENT BIOPHARMA, INC. showed an increase of +513.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2013: $13.49 million | Q2 2013: $10.78 million | Q3 2013: $7.69 million | Q1 2014: $56.97 million | Q2 2014: $66.22 million | Q3 2014: $61.36 million | Q1 2015: $46.57 million | Q2 2015: $40.23 million | Q3 2015: $53.76 million | Q1 2016: $38.83 million | Q2 2016: $53.09 million | Q3 2016: $45.28 million | Q4 2016: $40.04 million | Q1 2017: $34.59 million | Q2 2017: $119.15 million | Q3 2017: $112.87 million | Q1 2018: $242.63 million | Q2 2018: $229.43 million | Q3 2018: $219.83 million | Q1 2019: $195.56 million | Q2 2019: $184.17 million | Q3 2019: $170.89 million | Q1 2020: $154.82 million | Q2 2020: $149.84 million | Q3 2020: $142.87 million | Q1 2021: $132.47 million | Q2 2021: $118.85 million | Q3 2021: $101.92 million | Q1 2022: $76.52 million | Q2 2022: $60.24 million | Q3 2022: $51.62 million | Q1 2023: $65.00 million | Q2 2023: $58.04 million | Q3 2023: $49.41 million | Q1 2024: $31.28 million | Q2 2024: $22.39 million | Q3 2024: $14.39 million | Q1 2025: $5.61 million | Q3 2025: $133.27 million.
  • Over the full 15 years of available data (2011 to 2025), CRESCENT BIOPHARMA, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 656.7%.
  • Historical annual values: Fiscal year 2025: $213.19 million | Fiscal year 2024: $34.77 million | Fiscal year 2023: $41.79 million | Fiscal year 2022: $47.87 million | Fiscal year 2021: $90.25 million | Fiscal year 2020: $137.04 million | Fiscal year 2019: $158.20 million | Fiscal year 2018: $209.92 million | Fiscal year 2017: $123.92 million | Fiscal year 2016: $40.04 million | Fiscal year 2015: $46.80 million | Fiscal year 2014: $55.20 million | Fiscal year 2013: $2.31 million | Fiscal year 2012: $17.37 million | Fiscal year 2011: $28.17 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: